

## April 2024 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

**Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 6/1/2024.**

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
Xolair (omalizumab) 75 mg/0.5 mL, 150 mg/1 mL, & 300 mg/2 mL auto-injectors and prefilled syringes for IgE-mediated food allergy	Formulary	Formulary
Biktarvy (bictegravir-emtricitabine-tenofovir alafenamide) 50-200-25 mg & 30-120-15 mg tablets complete regimen for complete HIV-1 expanded indication	Formulary	Formulary
Tagrisso (osimertinib) 40 & 80 mg tablets for first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations in combination with pemetrexed and platinum-based chemotherapy	Formulary	Formulary
Onivyde (irinotecan liposome injection) 4.3 mg/mL IV solution for first-line treatment of metastatic pancreatic	Non -Formulary	Non-Formulary

## April 2024 Pharmacy & Therapeutics Committee Decisions

adenocarcinoma		
Keytruda (pembrolizumab) 25 mg/mL IV solution for FIGO stage III-IVA cervical cancer in combination with chemoradiotherapy	Non-Formulary	Non-Formulary
Keytruda (pembrolizumab) 25 mg/mL IV solution for hepatocellular carcinoma in patients previously treated with sorafenib full approval	Non-Formulary	Non-Formulary
Rybrevant (amivantamab) 50 mg/mL IV solution for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations full approval	Non-Formulary	Non-Formulary
Brukinsa (zanubrutinib) 80 mg capsules for relapsed or refractory follicular lymphoma	Formulary	Formulary
Praluent (alirocumab) 75 mg/mL & 150 mg/mL pre-filled pens indicated as an adjunct to diet and other LDL cholesterol lowering therapies in pediatric patients ≥ 8 years age expansion	Formulary	Formulary
Livmarli (maralixibat) 9.5 mg/mL oral solution for cholestatic pruritus in patients ≥ 5 years with progressive familial intrahepatic cholestasis (PFIC)	Non-Formulary	Non-Formulary
Xofluza (baloxavir marboxil) 40 & 80 mg tablets for the treatment of acute uncomplicated influenza in healthy or high risk patients ≥ 5 years	Formulary	Formulary

## April 2024 Pharmacy & Therapeutics Committee Decisions

Xhance (fluticasone propionate) 93 mcg nasal spray for chronic rhinosinusitis without nasal polyps in adults	Non-Formulary	Non-Formulary
Iclusig (ponatinib) 10, 15, 30, & 45 mg tablets in combo with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)	Formulary	Formulary

NEW GENERICS REVIEW		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
Bromsite ( <b>bromfenac</b> ) 0.075% ophthalmic solution for postoperative inflammation	Brand is NF for all LOB. Generic is only 10% less expensive  Generic is PDL controlled	Non-Formulary
Pradaxa ( <b>dabigatran</b> ) 110 mg capsule for anticoagulation	This strength not commonly used compared to 75mg and 150mg. PDL controlled	Non-Formulary
Emflaza ( <b>deflazacort</b> ) 6, 18, 30, & 36 mg oral tablets for Duchenne muscular dystrophy	High cost. Minor differences compared to prednisone	Non-Formulary
Alrex ( <b>loteprednol</b> ) 0.2% ophthalmic suspension for seasonal allergic conjunctivitis	Brand is NF for all LOB. Generic is only 10% less expensive  Generic is PDL controlled	Non-Formulary
Thiola EC ( <b>tiopronin</b> ) 100 mg & 300 mg delayed release tablets for homozygous cystinuria	Brand is NF for all LOB. No cost savings with generic.	Non-Formulary
Rectiv ( <b>nitroglycerin</b> ) 0.4% rectal	Brand is covered on Medicaid	Formulary

## April 2024 Pharmacy & Therapeutics Committee Decisions

ointment for chronic anal fissure		
Lotemax ( <b>loteprednol</b> ) 0.5% ophthalmic gel for postoperative inflammation and pain		Formulary

New or Expanded Formulations		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
Zoryve (roflumilast) 0.3% foam for seborrheic dermatitis	Topical antifungals and topical corticosteroids are most commonly used for seborrheic dermatitis	Non-Formulary
Omnipod 5 G7 intro kit & pods for insulin delivery	Allows connectivity with Dexcom G7	Formulary
Alvaiz (eltrombopag choline) 9, 18, 36, & 54 mg tablets for chronic immune thrombocytopenia (ITP), thrombocytopenia in hepatitis C, & severe aplastic anemia	No advantage over Promacta which is on formulary with an expected generic in the next few years.	Non-Formulary
Eohilia (budesonide) 2 mg/10 mL oral suspension for eosinophilic esophagitis (EoE)	Significantly higher cost compared to current treatment option with budesonide respules	Non-Formulary
CVS/Cordavis Humira (adalimumab) 80 mg/0.8 mL pen, 40 mg/0.4 mL pen and PFS, 20 mg/0.2 mL PFS, 10 mg/0.1 mL PFS for various conditions	No benefit to adding for any line of business.	Non-Formulary
Xolair (omalizumab) 75 mg/0.5 mL, 150 mg/1 mL, & 300 mg/2 mL auto-injectors and 300 mg/2 mL prefilled syringe for asthma, chronic spontaneous urticaria, & IgE-mediated food allergy	New dosage forms for omalizumab were launched, including auto-injectors in the 75 mg/0.5 mL and 150 mg/1 mL concentrations, adding to existing prefilled syringes in those strengths. A new 300 mg/2 mL concentration was	Formulary

## April 2024 Pharmacy & Therapeutics Committee Decisions

	also launched in both prefilled syringe and auto-injector forms.	
Hemlibra (emicizumab) 12 mg/0.4 mL subcutaneous injection for hemophilia	New strength added to formulary	Formulary
Yuflyma (adalimumab) 20 mg/0.2 mL for various inflammatory condition	PDL controlled. Not adding this biosimilar to other lines of business at this time.	Non-Formulary
Sovuna (hydroxychloroquine) 200 & 300 mg tablets for rheumatoid arthritis	Branded hydroxychloroquine. Generic is <\$1 per tab vs \$16.65 for Sovuna	Non-Formulary
RiVive (naloxone) 3 mg/0.1 mL nasal spray for opioid overdose	Adding another OTC naloxone option for IFP and Medicaid. Not MedD eligible	Non-Formulary
Opill (norgestrel) 0.075 mg tablet for contraception	OTC oral contraceptive. Adding for IFP and Medicaid in alignment with ACA. Not MedD eligible.	Non-Formulary
Simlandi (adalimumab) 40 mg/0.4 mL for various inflammatory conditions	PDL controlled (not addressed yet). Not adding this biosimilar to other lines of business at this time.	Non-Formulary

### ADDITIONAL ITEMS REVIEWED

ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 07/01/2024)	<ul style="list-style-type: none"> <li>• Ycanth</li> </ul>